Fair Value Calculator Fair Value Calculator
EN DE

MEDICAPQ (MEDICAPQ) Fair Value & Analysis

IN · Market cap ₹323M

M MEDICAPQ MEDICAPQ · BSE
Price₹25.93
Fair Value₹34.62
Upside+33.5%
Quality47/100
Watch MEDICAPQ for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹22.85 – ₹43.28

Fair value as of: Jul 5, 2026

From 1 valuation models · updated today

Share price −11.0% over the past month.

Price vs Fair Value (12 months)

₹44.57 ₹21.86 Fair Value ₹34.62 Jul 2025 Jul 2026

12‑month range ₹21.86 – ₹44.57 · fair‑value band ₹22.85 – ₹43.28 · the ₹25.93 price screens below the ₹34.62 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

MEDICAPQ (MEDICAPQ) currently trades at ₹25.93, while our model-based Fair Value estimate is ₹34.62 — implying the stock looks roughly 33.5% undervalued today. We read business quality at 47/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, MEDICAPQ generated revenue of ₹124M at a net margin of -24.4%. Revenue declined 50.5% year over year. It earns a return on equity of -2.6%. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹22.85 (bear case) to ₹43.28 (bull case); at ₹25.93, the current price sits within that range. The share trades about 45% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹124M
Revenue growth (YoY) -50.5%
Net margin -24.4%
Return on equity -2.6%
Free cash flow −₹78.7M FY2026
Operating margin -74.2%
More key figures
EPS (TTM) ₹-2.44
EPS growth (YoY) +77.1%
Net debt ₹619K FY2020

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

MEDICAPQ reported revenue of ₹124M in FY2026 versus ₹683M in FY2022, a compound −34.7%/yr. Reported net income was −₹30.4M in FY2026.

Revenue −34.7%/yr
FY22 ₹683M
FY23 ₹486M
FY24 ₹266M
FY25 ₹254M
FY26 ₹124M
Net income
FY22 ₹101M
FY23 ₹17.6M
FY24 −₹22.4M
FY25 −₹5.7M
FY26 −₹30.4M

Is MEDICAPQ fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "MEDICAPQ Fair Value". https://www.fairvalue-calculator.com/stock/MEDICAPQ

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is MEDICAPQ (MEDICAPQ) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹34.62 versus a price of ₹25.93 — about +34% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MEDICAPQ?
Our model-based fair value for MEDICAPQ is ₹34.62 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹25.93.
What is the quality score of MEDICAPQ?
MEDICAPQ has a Quality Score of 47/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of MEDICAPQ (MEDICAPQ)?
MEDICAPQ reported trailing-twelve-month revenue of about ₹124M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of MEDICAPQ?
The net profit margin of MEDICAPQ is about -24.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.